Perfect(603059)2025-01-17 10:30Financial Performance Expectations - The company expects a net loss attributable to shareholders of the parent company for 2024 to be between -84.6 million and -56.4 million RMB, indicating a loss compared to the previous year[4]. - The projected net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, is expected to be between -102.1 million and -68 million RMB[4]. - In the previous year, the total profit was 84.82 million RMB, and the net profit attributable to shareholders of the parent company was 92.51 million RMB[5]. - The earnings per share for the previous year was 0.92 RMB[5]. Impairment and Performance Issues - The anticipated losses are primarily due to fluctuations in the operating performance of the associated company, Weimei Zi Industrial (Guangdong) Co., Ltd., leading to expected impairment provisions for long-term equity investments[8]. - Impairment provisions for goodwill are expected due to the underperformance of the subsidiary, Shan'en Kang Biotechnology (Suzhou) Co., Ltd.[8]. Forecast and Audit Status - The performance forecast is based on preliminary calculations by the company's finance department and has not been audited by registered accountants[9]. - The asset impairment testing is still ongoing, and the amounts for goodwill and asset impairment provisions will be finalized based on the audit and assessment results[9]. - The forecast data is preliminary and the accurate financial data will be disclosed in the official 2024 annual report[10]. - Investors are advised to be cautious regarding investment risks due to the preliminary nature of the forecast[10].